References
- International Agency for Research on Cancer, World Health OrganizationGLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012International Agency for Research on Cancer2013 Available from: http://globocan.iarc.frAccessed July 10, 2014
- LiCIMaloneKEDalingJRDifferences in breast cancer stage, treatment, and survival by race and ethnicityArch Intern Med2003163495612523916
- BlumJLJonesSEBuzdarAUMulticenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancerJ Clin Oncol19991748549310080589
- ModiSCurrieVESeidmanADA phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneClin Breast Cancer20056556015899073
- ZelekLBarthierSRiofroMWeekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinomaCancer2001922267227211745280
- PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol2007253407341417606974
- MurphyCGSeidmanADEvolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanesClin Breast Cancer20099S58S6519596644
- JordanMAWilsonLMicrotubules as a target for anticancer drugsNat Rev Cancer2004425326515057285
- MorrisPGFornierMNMicrotubule active agents: beyond the taxane frontierClin Cancer Res2008147167717219010832
- TowleMJSalvatoKABudrowJIn vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin BCancer Res2001611013102111221827
- DabydeenDABurnettJCBaiRComparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulinMol Pharmacol2006701866187516940412
- KuznetsovGTowleMJChengHInduction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389Cancer Res2004645760576615313917
- KuznetsovGTenDykeKYuMJLittlefieldBAYuJLittlefieldBAAntiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitroAbstract C58 presented at the annual meeting of the American Association for Cancer ResearchApril 14–18, 2007Los Angeles, CA, USA
- NewmanSEribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancerCurr Opin Investig Drugs2007810571066
- ZhangZYKingBMPelletierRDWongYNDelineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4Cancer Chemother Pharmacol20086270771618431572
- SynoldTWMorganRJNewmanEMA phase I pharmacokinetic, target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trialJ Clin Oncol200523Suppl 200 Abstr 3036
- GoelSMitaACMitaMA Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumorsClin Cancer Res2009154207421219509177
- MukoharaTNagaiSMukaiHEribulin mesylate in patients with refractory cancers: a Phase I studyInvest New Drugs2012301926193321887501
- TanARRubinEHWaltonDCPhase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumorsClin Cancer Res2009154213421819509146
- DevrieseLAWitteveenPOMarchettiSPharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairmentCancer Chemother Pharmacol20127082383223010853
- VahdatLTPruittBFabianCJPhase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJ Clin Oncol2009272954296119349550
- CortesJVahdatLBlumJLPhase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabineJ Clin Oncol2010283922392820679609
- AogiKIwataHMasudaNA phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancerAnn Oncol2012231441144821989327
- McIntyreKO’ShaughnessyJSchwartzbergLPhase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancerBreast Cancer Res Treat201414632132824699910
- WilksSPuhallaSO’ShaughnessyJPhase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancerClin Breast Cancer622014 [Epub ahead of print]
- LaPointeNEMorfiniGBradySTFeinsteinSCWilsonLJordanMAEffects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathyNeurotoxicology20133723123923711742
- WozniakKMWuYFarahMHLittlefieldBANomotoKSlusherBSNeuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathyNeurotox Res20132433834423637052
- VahdatLGarciaAVogelCEribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathyBreast Cancer Res Treat201314034135123877339
- TwelvesCCortesJVahdatLTPhase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancerClin Breast Cancer20101016016320299316
- CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyLancet201137791492321376385
- US Food and Drug AdministrationHalaven™ (eribulin mesylate) injection2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdfAccessed July 10, 2014
- MussHCortesJVahdatLTEribulin monotherapy in patients aged 70 years and older with metastatic breast cancerOncologist20141931832724682463
- KaufmanPAAwadaATwelvesCA phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanesCancer Res20127224 Suppl Abstr S66
- CortesJAwadaAKaufmanPAQuality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized studyJ Clin Oncol201331Suppl Abstr 1050
- European Medicines AgencyAssessment report for Halaven (eribulin)2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002084/WC500105115.pdfAccessed July 10, 2014
- PeanEKlaarSBerglundEGThe European Medicines Agency review of Eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientifc assessment of the Committee for Medicinal Products for Human UseClin Cancer Res2012184491449722829199
- National Institute for Health and Clinical ExcellenceFinal appraisal determination on eribulin for the treatment of locally advanced or metastatic breast cancer2012 Available from: http://www.nice.org.uk/nicemedia/live/13238/57079/57079.pdfAccessed July 10, 2014
- National Centre for PharmacoeconomicsCost effectiveness of eribulin (Halaven®) for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease2012 Available from: http://www.ncpe.ie/wp-content/uploads/2011/03/Eribulin-HalavenSummary1.pdfAccessed July 10, 2014
- Pan-Canadian Oncology Drug Review. Initial economic guidance report Eribulin (Halaven) for metastatic breast cancer2012 Available from: http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-halaven-in-egr.pdfAccessed July 10, 2014
- RiveraEMejiaJAArunBKPhase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancerCancer20081121455146118300256
- SeidmanADBerryDCirrincioneCRandomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840J Clin Oncol2008261642164918375893
- JohnMHinkeAStauchMWeekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines – a phase II multipractice studyBMC Cancer20121216522559145
- BaselgaJCortésJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med201236610911922149875
- RugoHPhase Ib/II study of PLX 3397 and eribulin in patients with metastatic breast cancer Available from: http://clinicaltrials.gov/show/NCT01596751Accessed November 25, 2014
- Corcept TherapeuticsMifepristone and eribulin in patients with metastatic triple negative breast cancer or ovarian cancer Available from: http://clinicaltrials.gov/show/NCT02014337Accessed November 25, 2014
- Polyphor LtdDose escalation of POL6326 in combination with eribulin in patients with metastatic breast cancer Available from: http://clinicaltrials.gov/show/NCT01837095Accessed November 25, 2014
- LeeHMoffitt Cancer Center and Research InstituteA Phase I dose escalation study of eribulin plus weekly carboplatin for metastatic breast patients Available from: http://clinicaltrials.gov/show/NCT01795586Accessed November 25, 2014
- City of Hope Medical CenterEribulin mesylate and everolimus in treating patients with triple-negative metastatic breast cancer Available from: http://clinicaltrials.gov/show/NCT02120469Accessed November 25, 2014
- Dana-Farber Cancer InstitutePhase II study of eribulin mesylate, trastuzumab, and pertuzumab in women with metastatic, unresectable locally advanced, or locally recurrent HER2-positive breast cancer Available from: http://clinicaltrials.gov/show/NCT01912963Accessed November 25, 2014
- German Breast GroupEfficacy and tolerability of eribulin plus lapatinib in patients with metastatic breast cancer (E-VITA) Available from: http://clinicaltrials.gov/show/NCT01534455Accessed November 25, 2014
- University of WashingtonEribulin mesylate in treating patients with previously treated metastatic breast cancer Available from: http://clinicaltrials.gov/show/NCT01908101Accessed November 25, 2014
- Arcagy/Gineco GroupFirst line metastatic breast cancer treatment (ESMERALDA) Available from: http://clinicaltrials.gov/show/NCT01941407Accessed November 25, 2014
- Medica Scientia Innovation ResearchMonotherapy with eribulin in HER2 negative metastatic breast cancer as a first line treatment (MERIBEL) Available from: http://clinicaltrials.gov/show/NCT02061085Accessed November 25, 2014
- Asan Medical CenterEribulin plus gemcitabine vs paclitaxel plus gemcitabine in HER2-negative metastatic breast cancer Available from: http://clinicaltrials.gov/show/NCT02263495Accessed November 25, 2014
- Dana-Farber Cancer InstituteEribulin in HER2 negative metastatic BrCa Available from: http://clinicaltrials.gov/show/NCT01827787Accessed November 25, 2014
- Consorzio OncotechSafety and effcacy study of eribulin in combination with bevacizumab for second-line treatment HER2-MBC patients (GIM11-BERGI) Available from: http://clinicaltrials.gov/show/NCT02175446Accessed November 25, 2014
- TkaczukKTrastuzumab and pertuzumab alone or in combination with hormonal therapy or chemotherapy with eribulin in women aged 60 and over with HER2/Neu overexpressed locally advanced or MBC Available from: http://clinicaltrials.gov/show/NCT02000596Accessed November 25, 2014
- Eisai IncA randomized Phase III trial of eribulin compared to standard weekly paclitaxel as first- or second-line therapy for locally recurrent or metastatic breast cancer Available from: http://clinicaltrials.gov/show/NCT02037529Accessed November 25, 2014
- SOLTI Breast Cancer Research GroupPharmacogenomic study of neoadjuvant eribulin for HER2 non-overexpressing breast cancer (NeoEribulin) Available from: http://clinicaltrials.gov/show/NCT01669252Accessed November 25, 2014
- Eisai IncEribulin in combination with capecitabine for adjuvant treatment in estrogen receptor-positive early stage breast cancer Available from: http://clinicaltrials.gov/show/NCT01439282Accessed November 25, 2014
- Emory UniversityNeoadjuvant trial of eribulin followed by dose dense doxorubicin and cyclophosphamide for HER2-negative, locally advanced breast cancer Available from: http://clinicaltrials.gov/show/NCT01498588Accessed November 25, 2014
- M.D. Anderson Cancer CenterNeoadjuvant study of sequential eribulin followed by FAC compared to sequential paclitaxel followed by FEC in early stage breast cancer not overexpressing HER-2 Available from: http://www.clinicaltrials.gov/show/NCT0159302Accessed November 25, 2014
- TerashimaMSakaiKTogashiYSynergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell linesSpringer Plus2014341725140293
- MukaiHSaekiTShimadaKPhase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancerInvest New Drugs9232014 [Epub ahead of print]
- KoczywasMFrankelPHSynoldTWPhase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumorsBr J Cancer10282014 [Epub ahead of print]